CA2448763A1 - A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea - Google Patents
A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea Download PDFInfo
- Publication number
- CA2448763A1 CA2448763A1 CA002448763A CA2448763A CA2448763A1 CA 2448763 A1 CA2448763 A1 CA 2448763A1 CA 002448763 A CA002448763 A CA 002448763A CA 2448763 A CA2448763 A CA 2448763A CA 2448763 A1 CA2448763 A1 CA 2448763A1
- Authority
- CA
- Canada
- Prior art keywords
- ethoxy
- phenyl
- propanoic acid
- pharmaceutically
- sulfonylurea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101982-7 | 2001-06-01 | ||
| SE0101982A SE0101982D0 (sv) | 2001-06-01 | 2001-06-01 | Pharmaceutical combination |
| PCT/SE2002/001036 WO2002100413A1 (en) | 2001-06-01 | 2002-05-30 | A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2448763A1 true CA2448763A1 (en) | 2002-12-19 |
Family
ID=20284364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002448763A Abandoned CA2448763A1 (en) | 2001-06-01 | 2002-05-30 | A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20040157927A1 (ko) |
| EP (1) | EP1399166A1 (ko) |
| JP (1) | JP2004532891A (ko) |
| KR (1) | KR20040007624A (ko) |
| CN (1) | CN1250226C (ko) |
| BR (1) | BR0210127A (ko) |
| CA (1) | CA2448763A1 (ko) |
| CO (1) | CO5540382A2 (ko) |
| CZ (1) | CZ20033235A3 (ko) |
| EE (1) | EE200300583A (ko) |
| HU (1) | HUP0401613A3 (ko) |
| IL (1) | IL159035A0 (ko) |
| IS (1) | IS7057A (ko) |
| MX (1) | MXPA03011010A (ko) |
| NO (1) | NO20035235D0 (ko) |
| PL (1) | PL367890A1 (ko) |
| RU (1) | RU2003136157A (ko) |
| SE (1) | SE0101982D0 (ko) |
| SK (1) | SK14722003A3 (ko) |
| WO (1) | WO2002100413A1 (ko) |
| ZA (1) | ZA200309263B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ｐｐａｒ調節剤およびそのスクリーニング方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| US6552055B2 (en) * | 1996-12-11 | 2003-04-22 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
-
2001
- 2001-06-01 SE SE0101982A patent/SE0101982D0/xx unknown
-
2002
- 2002-05-30 MX MXPA03011010A patent/MXPA03011010A/es unknown
- 2002-05-30 WO PCT/SE2002/001036 patent/WO2002100413A1/en not_active Application Discontinuation
- 2002-05-30 RU RU2003136157/15A patent/RU2003136157A/ru not_active Application Discontinuation
- 2002-05-30 BR BR0210127-0A patent/BR0210127A/pt not_active IP Right Cessation
- 2002-05-30 EP EP02736370A patent/EP1399166A1/en not_active Withdrawn
- 2002-05-30 US US10/479,205 patent/US20040157927A1/en not_active Abandoned
- 2002-05-30 JP JP2003503234A patent/JP2004532891A/ja not_active Withdrawn
- 2002-05-30 CA CA002448763A patent/CA2448763A1/en not_active Abandoned
- 2002-05-30 HU HU0401613A patent/HUP0401613A3/hu unknown
- 2002-05-30 CZ CZ20033235A patent/CZ20033235A3/cs unknown
- 2002-05-30 PL PL02367890A patent/PL367890A1/xx not_active Application Discontinuation
- 2002-05-30 EE EEP200300583A patent/EE200300583A/xx unknown
- 2002-05-30 KR KR10-2003-7015644A patent/KR20040007624A/ko not_active Application Discontinuation
- 2002-05-30 SK SK1472-2003A patent/SK14722003A3/sk not_active Application Discontinuation
- 2002-05-30 IL IL15903502A patent/IL159035A0/xx unknown
- 2002-05-30 CN CNB028149882A patent/CN1250226C/zh not_active Expired - Fee Related
-
2003
- 2003-11-25 NO NO20035235A patent/NO20035235D0/no not_active Application Discontinuation
- 2003-11-27 ZA ZA200309263A patent/ZA200309263B/en unknown
- 2003-11-28 IS IS7057A patent/IS7057A/is unknown
- 2003-12-23 CO CO03112113A patent/CO5540382A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5540382A2 (es) | 2005-07-29 |
| MXPA03011010A (es) | 2004-02-27 |
| IL159035A0 (en) | 2004-05-12 |
| IS7057A (is) | 2003-11-28 |
| CZ20033235A3 (cs) | 2004-12-15 |
| ZA200309263B (en) | 2005-03-11 |
| EP1399166A1 (en) | 2004-03-24 |
| KR20040007624A (ko) | 2004-01-24 |
| BR0210127A (pt) | 2004-06-08 |
| WO2002100413A1 (en) | 2002-12-19 |
| EE200300583A (et) | 2004-02-16 |
| NO20035235D0 (no) | 2003-11-25 |
| CN1537008A (zh) | 2004-10-13 |
| JP2004532891A (ja) | 2004-10-28 |
| RU2003136157A (ru) | 2005-05-20 |
| SK14722003A3 (sk) | 2004-08-03 |
| CN1250226C (zh) | 2006-04-12 |
| HUP0401613A2 (hu) | 2004-11-29 |
| HUP0401613A3 (en) | 2007-11-28 |
| PL367890A1 (en) | 2005-03-07 |
| US20040157927A1 (en) | 2004-08-12 |
| SE0101982D0 (sv) | 2001-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thompson et al. | Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin | |
| EP1928499B1 (en) | Use of a dpp-iv inhibitor to reduce hypoglycemic events | |
| Kirpichnikov et al. | Metformin: an update | |
| BG106732A (bg) | Фармацевтичен състав с антидиабетично действие и метод за лечение на диабет | |
| JP2001510159A (ja) | チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療 | |
| Drogovoz et al. | Potential risks and pharmacological safety features of hypoglycemic drugs | |
| US20040147600A1 (en) | Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin | |
| EP1404309B1 (en) | A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl| propanoic acid or 3- 4- 2- (4-tert-butoxy carbonyl aminophenyl) ethoxy| phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug | |
| US20040157927A1 (en) | Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{-4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and a sulonylurea | |
| SK612000A3 (en) | Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition | |
| AU2002309398A1 (en) | A pharmaceutical combination comprising either (S)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea | |
| AU2002309399A1 (en) | A pharmaceutical combination comprising either (S)-2-ethoxy -3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(S)-2-ethoxy propanoic acid and insulin | |
| AU2002258332A1 (en) | A pharmaceutical combination comprising either (S)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(S)-2-ethoxy propanoic acid and a biguanide drug | |
| US10292949B2 (en) | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction | |
| JP4914714B2 (ja) | 脂質代謝異常の予防または治療用医薬組成物 | |
| Svitlana et al. | Potential risks and pharmacological safety features of hypoglycemic drugs | |
| Kurebayashi et al. | Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |